In conclusion, risk of all-cause, cardiovascular, and cancer mortality associated with insulin therapy in patients with type 2 diabetes, was significantly lower with detemir and glargine in comparison with NPH use. This evidence concerns the gene INS and type 2 diabetes mellitus.